AU2001241183A1 - Amide compounds and use thereof - Google Patents

Amide compounds and use thereof

Info

Publication number
AU2001241183A1
AU2001241183A1 AU2001241183A AU4118301A AU2001241183A1 AU 2001241183 A1 AU2001241183 A1 AU 2001241183A1 AU 2001241183 A AU2001241183 A AU 2001241183A AU 4118301 A AU4118301 A AU 4118301A AU 2001241183 A1 AU2001241183 A1 AU 2001241183A1
Authority
AU
Australia
Prior art keywords
compound
drug
shows
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001241183A
Inventor
Koshiro Katayama
Yoichiro Naito
Shinichi Takanashi
Hiroshi Tanaka
Masayoshi Uehata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Welfide Corp filed Critical Welfide Corp
Publication of AU2001241183A1 publication Critical patent/AU2001241183A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

The present invention relates to an amide compound of the formula <CHEM> wherein R<1> is a hydrogen and the like, R<2> is a hydrogen and the like, X is SO2 and the like, Y is the formula (III) and the like and a is 2, an isomer thereof or pharmaceutically acceptable salts thereof. The compound of the present invention shows a remarkable and selective Rho kinase inhibitory action, is free of problematic toxicity, shows fine oral absorption and drug kinetics (absorption, distribution, metabolism, excretion and the like of the drug), and shows superior properties (e.g., stability etc.) as a compound. Accordingly, it can be used as a therapeutic drug for various diseases in which Rho kinase is involved.
AU2001241183A 2000-03-16 2001-03-16 Amide compounds and use thereof Abandoned AU2001241183A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-074764 2000-03-16
JP2000074764 2000-03-16
PCT/JP2001/002132 WO2001068607A1 (en) 2000-03-16 2001-03-16 Amide compounds and use thereof

Publications (1)

Publication Number Publication Date
AU2001241183A1 true AU2001241183A1 (en) 2001-09-24

Family

ID=18592757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001241183A Abandoned AU2001241183A1 (en) 2000-03-16 2001-03-16 Amide compounds and use thereof

Country Status (16)

Country Link
US (1) US6933305B2 (en)
EP (1) EP1270570B1 (en)
JP (1) JP4776136B2 (en)
KR (2) KR100818061B1 (en)
CN (1) CN1198804C (en)
AT (1) ATE327993T1 (en)
AU (1) AU2001241183A1 (en)
CA (1) CA2403321C (en)
CY (1) CY1105575T1 (en)
DE (1) DE60120138T8 (en)
DK (1) DK1270570T3 (en)
ES (1) ES2266171T3 (en)
HK (1) HK1049837B (en)
PT (1) PT1270570E (en)
SI (1) SI1270570T1 (en)
WO (1) WO2001068607A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1378247B1 (en) * 2001-04-11 2016-08-24 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
JPWO2003082808A1 (en) * 2002-04-03 2005-08-04 住友製薬株式会社 Benzamide derivatives
AU2003249534A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
ATE525111T1 (en) * 2003-04-18 2011-10-15 Senju Pharma Co 2-CHLORO-6,7-DIMETHOXY-N-5 Ä5-(1)H-INDAZOLYLUQUINAZOLINE-4-AMINE, N-(1-BENZYL-4-PIPERIDINYL)-1H-INDAZOLE-5-AMINE DIHYDROCHLORIDE, 4-Ä2 -(2,3,4,5,6-
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
CN100390173C (en) * 2003-06-06 2008-05-28 旭化成制药株式会社 Tricyclic compound
TWI346112B (en) * 2004-02-25 2011-08-01 Nissan Chemical Ind Ltd Benzopyran compound
WO2007076360A1 (en) 2005-12-22 2007-07-05 Alcon Research, Ltd. (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
EP1830853B1 (en) * 2004-12-27 2011-08-10 Novartis AG Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
CR9465A (en) * 2005-03-25 2008-06-19 Surface Logix Inc PHARMACOCINETICALLY IMPROVED COMPOUNDS
US8629161B2 (en) 2005-06-21 2014-01-14 Kowa Co., Ltd. Preventive or remedy for glaucoma
US8193193B2 (en) 2005-07-12 2012-06-05 Kowa Co., Ltd. Agent for prevention or treatment of glaucoma
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
EP1891958A1 (en) * 2006-08-03 2008-02-27 Universite Pierre Et Marie Curie (Paris Vi) Rho/Rock/PI3/Akt kinase inhibitors for the treatment of diseases associated with protozoan parasites.
WO2008049000A2 (en) * 2006-10-18 2008-04-24 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
JP2011507851A (en) * 2007-12-19 2011-03-10 ザ スクリプス リサーチ インスティチュート Benzimidazoles and analogs as Rho kinase inhibitors
US20110038835A1 (en) * 2007-12-21 2011-02-17 The Scripps Research Institute Anilides and analogs as rho kinase inhibitors
CA2709918A1 (en) * 2007-12-21 2009-06-25 The Scripps Research Institute Benzopyrans and analogs as rho kinase inhibitors
EP2628482A1 (en) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho kinase inhiitors for use in the treatment of neuroblastoma
US11001564B2 (en) * 2016-09-13 2021-05-11 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
JP7416700B2 (en) 2017-11-14 2024-01-17 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド Methods of RUNX1 inhibition for the treatment of conditions associated with proliferative vitreoretinopathy and epithelial-mesenchymal transition
EP3843845A4 (en) 2018-08-29 2022-05-11 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL331561A1 (en) 1996-08-12 1999-07-19 Yoshitomi Pharmaceutical Pharmaceutic composition containing an inhibitor of rho kinase
JPH11130751A (en) * 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd Labeled compound of amide compound and acid adduct salt thereof
JP2000063274A (en) * 1998-08-20 2000-02-29 Yoshitomi Pharmaceut Ind Ltd Inhalant for asthma control

Also Published As

Publication number Publication date
DE60120138T8 (en) 2007-10-11
ATE327993T1 (en) 2006-06-15
EP1270570B1 (en) 2006-05-31
DK1270570T3 (en) 2006-10-02
CN1198804C (en) 2005-04-27
ES2266171T3 (en) 2007-03-01
US20030158413A1 (en) 2003-08-21
CA2403321A1 (en) 2001-09-20
DE60120138D1 (en) 2006-07-06
HK1049837A1 (en) 2003-05-30
EP1270570A4 (en) 2004-02-18
KR20070087087A (en) 2007-08-27
PT1270570E (en) 2006-10-31
KR100818061B1 (en) 2008-04-01
DE60120138T2 (en) 2007-03-29
CN1418194A (en) 2003-05-14
KR100818060B1 (en) 2008-03-31
CA2403321C (en) 2009-07-14
US6933305B2 (en) 2005-08-23
SI1270570T1 (en) 2006-10-31
WO2001068607A1 (en) 2001-09-20
CY1105575T1 (en) 2010-07-28
JP4776136B2 (en) 2011-09-21
EP1270570A1 (en) 2003-01-02
HK1049837B (en) 2007-01-19
KR20020081455A (en) 2002-10-26

Similar Documents

Publication Publication Date Title
AU2001241183A1 (en) Amide compounds and use thereof
WO2002080846A3 (en) Epothilone derivatives and methods for making and using the same
CA2401229A1 (en) Aryl fused azapolycyclic compounds
WO2005037825A3 (en) Protein kinase inhibitors
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
SE0104332D0 (en) Therapeutic agents
LU91761I2 (en) Vernakalant and its pharmaceutically acceptable derivatives and in particular its hydrochloride salt (BRINAVESS®)
CA2510853A1 (en) Pyrrolopyrimidine derivatives
CA2333703A1 (en) Isothiazole derivatives useful as anticancer agents
CA2313122A1 (en) Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
CA2414018A1 (en) 2-aminocarbonyl-9h-purine derivatives
MXPA02011974A (en) Substituted quinazoline derivatives and their use as inhibitors.
SE0104334D0 (en) Therapeutic agents
WO2002057252A3 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
WO2004096134A3 (en) Substituted 1,4-diazepines and uses thereof
HK1155146A1 (en) Indene derivatives as pharmaceutical agents
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
TNSN04165A1 (en) Substituted hydroxyethylamines
CA2373117A1 (en) 13-methyl-erythromycin derivatives
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists